An 11-year-old girl with Ph؉ CML received a marrowablative cytoreductive regimen, but both blood and marrow grafts obtained from her two-loci-mismatched father were rejected. At the third attempt, she was directly injected with purified CD34 ϩ blood cells from the same donor into the bone marrow cavity with regular disposable bone marrow biopsy needles. The peripheral hemogram recovered rapidly thereafter, and she maintained stable complete donor type hematopoiesis until 8 months later, when she developed renal failure due to thrombotic microangiopathy, which was the primary cause of her death. This experience suggests that we revisit an old maneuver in the light of new developments.
When bone marrow transplantation was first developed, the direct injection of the graft into the bone marrow space was considered to be a very appropriate maneuver, as extensively reviewed by Hagglund et al. 1 However, the large amount of cell suspension required eventually prevented the widespread use of this procedure, and i.v. infusion is currently the preferred approach. Techniques for the positive selection/enrichment of CD34 ϩ cells from marrow or peripheral blood cells provide a convenient method for concentrating hematopoietic progenitors and depleting T cells. With the recent development of this cell purification technique, the use of direct inoculation may now be feasible.
Case report
An 11-year-old girl with Phϩ chronic myelogenous leukemia was induced into a complete hematological remission by hydroxyurea and interferon-␣. Since she had no related or unrelated HLA-matched donor available, an alternate transplant procedure with enriched blood CD34 ϩ cells obtained from her two-loci-mismatched father was chosen, with consent. Peripheral blood cells were mobilized by recombinant granulocyte colony-stimulating factor (G-CSF: 10 g/kg/day for 5 days) and collected by three aphereses. Then, CD34 ϩ cells were enriched using an immunomagnetic procedure with the Isolex 300 system (Baxter, Tokyo, Japan) and cryopreserved. A back-up marrow from the same donor was also cryopreserved. After the preconditioning with lung-shielded 12 Gy total body irradiation and 120 mg/kg cyclophosphamide (CY) treatment, 7.7 ϫ 10 . However, the graft was rejected at day 28, which was confirmed by the absence of the Y chromosome using FISH analysis. Then, she received cryopreserved bone marrow from the same donor. Nevertheless, autologous recovery of hematopoiesis, in the absence of the Phϩ clone, was confirmed 3 months later by the same FISH analysis. With a gradual increase of Ph ϩ cells 8 months after the first transplant, third transplantation was performed at 10 months, after preconditioning with the combination of busulfan 8 mg/kg, 9 Gy total lymphoid irradiation, 10 mg/kg antithymocyte globulin and CY 120 mg/kg. Once again, the same donor had his peripheral blood cells mobilized with G-CSF as above and CD34 ϩ cells were purified and cryopreserved. To avoid the risk of graft rejection, this time the graft, which contained 5.6 ϫ 10 6 /kg CD34 ϩ cells and 1.0 ϫ 10 5 /kg CD3 ϩ cells in 34 ml suspension with 100 mg of cefoperazone/sulbactam and 10 mg fluconazole, was directly injected into the recipient's bone marrow cavity in the bilateral post-iliac crests by puncturing two separate points with regular disposable bone marrow biopsy needles. All procedures were approved by the Institutional Review Board and a written informed consent was obtained from the parent. Post-transplant GVHD prophylaxis was the same as for the first transplantation and G-CSF was used. No immediate toxicities were observed and the patient's clinical course was uneventful. The number of days required to achieve an AGC of 0.5 ϫ 10 9 /l and a platelet count of 50 ϫ 10 9 /l were both 14 ( Figure 1 ). On day 10, she developed acute GVHD of the skin (grade 2), which responded to treatment with prednisolone alone. Donor type hematopoiesis was confirmed by sex chromosome identification on day 18. In an attempt to induce a graft-versusleukemia (GVL) effect, donor lymphocyte add-back infusion (DLI) was performed on days 36, 48 and 74 with 1.0 ϫ 10 5 /kg CD3 ϩ cells, respectively, as an integral part of the protocol. She then maintained stable complete donor type hematopoiesis until 8 months later, when she developed renal failure due to thrombotic microangiopathy, which was the primary cause of her death. During this course, she had maintained complete cytogenetic response with disappearance of major bcr-abl chimeric mRNA.
Discussion
As a common practice, stem cell products are infused into the venous system via central vein catheters following myeloablative chemoradiotherapy. It is likely that in this case only a limited portion of cells enter into the marrow space, since many cells are trapped in the microcirculation including the reticuloendothelial system, pulmonary vessels and other capillary beds during the first pass through the systemic circulation. This incident is likely on lungshielded TBI, because there are many active macrophages on these areas. Therefore, there has been an assumption that direct puncture of the marrow cavity to implant the graft might provide a more stable engraftment. Recently, Hagglund et al 1 revisited the old maneuver and performed a randomized study with 38 patients to examine whether direct injection of allogeneic graft into the recipient's bone marrow cavity accelerated engraftment. As a result, they reported that engraftment speed was similar to patients who received graft intravenously. However, it is very likely that intramedullary injection of an unmanipulated graft in a large volume soon fills the narrow marrow space and then, for the most part overflows into the peripheral circulation by mechanical pressure, leading to no difference at all between the two types of procedures. We then made a hypothesis that direct puncture of the marrow cavity to implant the graft, rather than systemic intravenous administration, guarantees more stable engraftment in clinical transplantation, only when cells are purified to reduce the total volume of the grafts. However, when the harvested graft is manipulated, the loss of cells is significant with donations containing only half of the initial inoculum and graft failure becoming of major concern. 2 In the study performed by Hagglund et al, 5 ml of unmanipulated marrow graft was radiolabeled and administered by intramedullary injection. Although a follow-up scintigraphic examination revealed that radiolabeled marrow cells spread in the skeleton as fast as i.v.-infused cells, a high focal activity at the site of osseous injection was recorded for at least 24 h. They did not compare the distribution of radiolabeled cells between osseous and i.v. injection in commonly cited trapping sites, such as the lung, liver and spleen. Our speculation that, after avoiding initial non-specific and very efficient trapping by non-hematopoietic tissues, intramedullary injected stem cells travel via the peripheral circulation for a wider distribution in hematopoietic tissue, does not appear to be contradicted.
The contribution of this alternative procedure to stable engraftment needs to be clarified, since in the third transplantation in the present case, the conditioning regimen was intensified to prevent graft rejection. Nevertheless, the feasibility of continuing to evaluate this idea was suggested in the absence of toxicities. In the study reported by Hagglund et al, 1 bacteremia was not observed in patients who received an intramedullary graft, while this was observed in 30% of patients who received the graft intravenously. However, to overcome the theoretical risk of complication by osteomyelitis, 3, 4 this procedure needs to strictly adhere to sterile techniques.
Although the cause of thrombotic microangiopathy in this patient remains unclear, it appears to be multifactorial. The repeated high-dose therapy and prolonged immune dysfunction inevitably associated with transplantation with purified CD34 ϩ cells, 5 either by themselves or complicated by viral infections, are likely causes of thrombotic microangiopathy. In addition, the preceding DLI may play an etiological role. It is unlikely that the intramedullary injection of cells has any direct etiological role in the development of thrombotic microangiopathy. To clarify this point, additional data will be required.
